The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric Cancer

February 28, 2025 updated by: Dong Peng

Identification of Paraneoplastic and Intratumor Microplastics in Gastric Cancer and Their Association Analysis with Macrogenomics and Metabolomics

The aim of this study was to identify and quantify microplastics in blood, stool, and tumor surgical specimens from gastric cancer patients by analyzing the nature, type, and abundance of microplastics using laser direct infrared (LDIR) spectroscopy, scanning electron microscopy (SEM), and pyrolysis-gas chromatography-mass spectrometry (Py-GC/MS). Meanwhile, combining macro-genomic and metabolomic techniques to explore the association between microplastics and host microbiota and metabolic profiles, and to reveal the potential effects of microplastics on gastric cancer incidence and development will provide new insights into the relationship between microplastic contamination and gastric cancer, as well as an important scientific basis for future public health strategies and cancer prevention and control measures.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

This This study is planned to collect blood, cancer and paracancer tissues, and stool samples from 20 patients with gastric cancer, 2 gastric cancer tissues (at least 1cm^3 each), 2 gastric paracancer tissues (at least 1cm^3 each), 2 venous bloods (5ml each), and 1 stool (at least 10g each) from each patient. Samples will be collected from December 2024 through November 2025, with an expected total of 140 samples. Sample collection, transportation, and storage are described in IV.2. & 3. Samples will be analyzed for the type, nature, and abundance of microplastics by Laser Direct Infrared Spectroscopy (LDIR), Scanning Electron Microscopy (SEM), and Pyrolysis-Gas Chromatography-Mass Spectrometry (Py-GC/MS), which is expected to detect microplastics such as polyamides, polyethylene terephthalate (PET), and polyvinyl chloride (PVC). At the same time, blood and tissue samples will be metabolomically assayed using NNR-IVD technology and macro-genomic sequencing will be performed to explore potential associations between microplastics and microbiota and metabolic pathways in gastric cancer patients. By analyzing the distribution characteristics of microplastics in gastric cancer patients and their relationship with microbial communities and metabolic pathways, this study will reveal the impact of microplastics on the tumor microenvironment and further understand their role in gastric cancer development and progression.

Study Type

Observational

Enrollment (Estimated)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Chongqing
      • Chongqing, Chongqing, China, 400016
        • The First Affiliated Hospital of Chongqing Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed with colorectal cancer by pathological biopsy were included in the study.

Description

Inclusion Criteria:

  • age ≥18 years old;
  • diagnosed with gastric cancer by pathology before surgery and not receiving chemotherapy, radiotherapy or immunotherapy;
  • no history of other gastrointestinal diseases;
  • complete clinical data and basic information;
  • willing to participate in this study and sign an informed consent form.

Exclusion Criteria:

  • Patients receiving neoadjuvant radiotherapy or chemotherapy;
  • patients with other malignant tumors other than gastric cancer;
  • patients with incomplete or unclear pathological data;
  • individuals who are not willing to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
the gastric cancer group
patients diagnosed with gastric cancer
Diagnostic test: gastric cancer
Patients diagnosed with gastric cancer by pathological biopsy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Types of microplastics in gastric cancerous and paracancerous tissues (categorical measure)
Time Frame: The date of microplastics testing, assessed up to 1 week after surgery.
Polymer types of microplastics in gastric tissues Time Frame: Intraoperative sampling Measuring tool: μ-FTIR spectroscopy Unit: Categorical classification (e.g., polyethylene, polypropylene, etc.)
The date of microplastics testing, assessed up to 1 week after surgery.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical-chemical properties of microplastics in gastric cancerous and paracancerous tissues (continuous measure)
Time Frame: The date of microplastics testing, assessed up to 1 week after surgery.
Morphological characteristics of microplastics in gastric tissues Time Frame: Intraoperative sampling Measuring tool: Optical microscopy Unit: Size (μm), shape distribution (%)
The date of microplastics testing, assessed up to 1 week after surgery.
Abundance of microplastics in gastric cancerous and paracancerous tissues (count/particles per gram)
Time Frame: The date of microplastics testing, assessed up to 1 week after surgery.
Microplastic abundance in gastric tissues Time Frame: Intraoperative sampling Measuring tool: Gravimetric analysis/particle counting Unit: Particles per gram tissue
The date of microplastics testing, assessed up to 1 week after surgery.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Dong Peng

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2024

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

February 25, 2025

First Submitted That Met QC Criteria

February 28, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 28, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024-530-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data sharing is not permitted by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Cancers

Clinical Trials on gastric cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe